CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Immunocore Holdings PLC - ADR is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Immunocore Holdings PLC - ADR
90 Park Drive, Milton Park, Abingdon
Phone: +44 1235438600p:+44 1235438600 ABINGDON, OX14 4RY  United Kingdom Ticker: IMCRIMCR
Business Summary
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board JohnBell 71 3/1/2015 3/1/2015
Chief Executive Officer, Executive Director BahijaJallal 62 1/1/2019 1/1/2019
Chief Financial Officer, Head of Strategy BrianDi Donato 57 4/1/2020 4/1/2020
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Immunocore Commercial LLC. 6 TOWER BRIDGE SUITE 200,181 WASHINGTON ST CONSHOHOCKEN PA UNITED STATES

Business Names
Business Name
IMCR
Immunocore Commercial LLC
Immunocore GmbH
Immunocore Ireland Limited
Immunocore LLC
Immunocore Nominees Limited England and Wales

General Information
Number of Employees: 497 (As of 12/31/2023)
Outstanding Shares: 50,032,770 (As of 10/31/2024)
Shareholders: 37
Stock Exchange: NASD
Email Address: info@immunocore.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024